Immunocure

Immunocure is a preclinical drug discovery Contract Research Organization (CRO) that utilizes its proprietary generative AI platform, AxDrug, integrated with computational chemistry and synthetic chemistry capabilities. The company’s approach involves analyzing molecular systems at an atomic level to generate insights, hypotheses, and optimized lead candidates. By employing machine learning, deep learning, and computer-aided drug design (CADD), Immunocure automates various stages of the drug discovery process, including target identification, hit-to-lead optimization, and ADMET filtering, aiming to improve success rates while reducing project timelines and research costs.

The company provides services to biopharma organizations, assisting in the development of small molecules, PROTACs, peptides, and other therapeutics across diverse areas such as oncology, immuno-oncology, and CNS disorders. By delivering end-to-end support from early-stage discovery to preclinical development, Immunocure helps partners accelerate their pipelines. Their expertise and technology have been utilized by research institutions and commercial collaborators for projects involving complex molecular design, structural optimization, and iterative synthesis, serving as a partner for organizations seeking to streamline discovery through data-driven and AI-powered solutions.